Work

A stimulus actuated polymeric device for the prolonged therapeutic management of moderate to severe chronic pain

Year: 2012
Type: dissertation
Abstract: Chronic pain may be defined as pain which persists in a patient for a prolonged period of time. \nAlthough this period of time may range from 3-12 months, it is most commonly described as pain \nwhich extends beyond the time required for healing. Chronic pain may also be classified into two \ndifferent categories depending on the cause. The first category is nociceptive, which is chronic pain \ncaused by activation of nociceptors. This may be due to several factors such as trauma or \ntemperature. The second category is neuropathic chronic pain. These are chronic pains which are not \nnecessarily caused by trauma, but more likely due to the malfunction of the nervous system. For this \nstudy, our aim is to develop a patient-controlled, externally actuated hydrogel system which is capable \nof ‘ON-OFF’ drug release. The model drug which was incorporated into the SAPD was a Non- \nSteroidal Anti-Inflammatory Drugs (NSAID), and thus our drug release system would be beneficial \nprimarily for nociceptive chronic pain. This subcutaneously implanted SAPD is produced with an \nelectroactive polymer which allows drug release in the presence of electrical stimulation. This would \nresult in direct availability of drug at the site of actuation with reduced side-effects and increased drug \nbio-availability. \nThe SAPD was formed by crosslinking polyvinyl alcohol (PVA) with diethyl acetamidomalate (DAA). \nThe result was a hydrogel which was capable of swelling while remaining insoluble when placed in \nvarious solvents. After the hydrogel was synthesized, indomethacin was incorporated as the model \ndrug. Indomethacin exhibited superior Drug Entrapment Efficiency (DEE) (±70-90%) and responsive \nrelease in the presence of an electrical stimulus. Finally, polyaniline (PANi) was used as the \nelectroactive polymer in order to enhance the conductivity and allow sufficient release of the drug. \nOptimization of the SAPD was undertaken with a 3-factor Box-Behnken Design which measured the \nrate of erosion, drug release and DEE. The optimized SAPD was synthesized using PVA (0.8g) \ncrosslinked with DAA (0.0689g) and a concentration of 1.3418%w/w PANi. Indomethacin was used and \nthe DEE achieved was 76.32±10.46% (target 80.5381%). The drug release profile was \n1.622%±0.1857% (target 1.7%) per release cycle and erosion rate was 5.73±1.26% (target 6.3201%) \nwhen actuated with a potential difference of 1V for a duration of 1 minute. \nChemometric modelling performed on the SAPD showed that drug release may be attributed to \nerosion of the SAPD in the presence of an electrical stimulus. The polymeric strands usually rest as a \ncoiled state within the SAPD. This coiled state may be the reason the hydrogel remained intact in the \nabsence of electrical stimulation. However, external electrical fields may adduct to form a coil rather \nthan an extended chain resulting in the formation of a globular aniline-vinyl complex. This formation \nthus leads to a weakened form of the hydrogel structure, resulting in breakdown and ultimately \nerosion. This erosive phenomenon ceased once the electrical stimulation was removed. The end \nresult of this hydrogel erosion is the liberation of the entrapped indomethacin. \nIn vivo animal studies on the SAPD indicated an ‘ON-OFF’ drug release profile. The drug release was \nconsistent and drug quantity of ±0.15mg per release cycle in the Sprague-Dawley rat model. The \nSAPD was implanted subcutaneously under the left flank and an electrical stimulation was triggered \nwith the use of a 2-in-1 galvano/potentiostat in order to ensure the electrical stimulus was constant. \nThe potential difference used was 1V over a period of 1 minute. The rats were assessed for signs of \nillness or swelling after the implantation procedure to determine the biocompatibility of the SAPD. The \nrats were monitored for 10 days and weighed daily. Results have shown that the rats did not \nexperience any considerable swelling and the weights of each rat were steady, thus indicating \nbiocompatibility of the SAPD. Histopatholgical samples indicated mild inflammation around the site of \nimplantation 10 days after implantation. This may have been due to minor surgery at site of \nimplantation. The biocompatibility of the SAPD was generally good and there were no signs of tumour \nor long term tissue inflammation. Future application of the SAPD may include an external actuation \ndevice to be worn as a watch which allows actuation of the SAPD when required by the patient.
Language: English
Subfield: Biomaterials
Open Access status: green
OpenAlex ID: W9562914
Cites: 268
Cited by:
Related to: 10